ReviewGels (Basel, Switzerland)2022
Recent Advances in Hydrogels for the Diagnosis and Treatment of Dry Eye Disease.
Review in Gels (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 31 citations in OpenAlex.
- Rebuilding Ocular Surface Lubrication with a Light-Triggered Hydration-Lubricating Nanoplatform for Dry Eye Disease Therapy.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Dual-Responsive Chitosan-Grafted PNIPAAm Hydrogel Eye Drop Incorporating Insulin-Imprinted Microgels for Dry Eye Syndrome Treatment.Macromolecular bioscience · 2026Article
- Hydrogel-based delivery of MSCs and derivatives for improved diabetic retinopathy therapy.Stem cell research & therapy · 2026Review
- Hydrogels-Advanced Polymer Platforms for Drug Delivery.Polymers · 2026Review
- Bridging Preclinical and Clinical Gaps in Ocular Therapeutics: Hydrogel Drug Delivery and 3D Tissue Models.International journal of nanomedicine · 2026Review
- Advances in loading-release-repair strategies of hydrogels for anterior segment disease therapy.Frontiers in immunology · 2026Review
- Advances in hydrogel-mediated gene therapy in ophthalmology: future directions and therapeutic potential.Regenerative biomaterials · 2026Review
- Review
- Advances in adhesive hydrogels applied for ophthalmology: An overview focused on the treatment.Theranostics · 2025Review
- Nanomedicines for Dry Eye Syndrome: Targeting Oxidative Stress with Modern Nanomaterial Strategies.Molecules (Basel, Switzerland) · 2024Review
- Preliminary study of cyclosporine A/Lifitegrast subconjunctival sustained-release drug membrane in the treatment of dry eyes.Eye and vision (London, England) · 2024Article
- Recent Advances in Nanotechnology for the Treatment of Dry Eye Disease.Nanomaterials (Basel, Switzerland) · 2024Review
- Mucoadhesive, antioxidant, and lubricant catechol-functionalized poly(phosphobetaine) as biomaterial nanotherapeutics for treating ocular dryness.Journal of nanobiotechnology · 2024Article
- Achieving net-zero in the dry eye disease care pathway.Eye (London, England) · 2024Review
- Newer approaches to dry eye therapy: Nanotechnology, regenerative medicine, and tissue engineering.Indian journal of ophthalmology · 2023Review
- Extended Intraocular Drug-Delivery Platforms for the Treatment of Retinal and Choroidal Diseases.Journal of vitreoretinal diseasesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Dry eye disease (DED) is the most common clinical ocular surface disease. Given its multifactorial etiology, no consensus has been reached on the diagnosis criteria for dry eye disease. Topical drug administration remains the mainstay of treatment but is limited to the rapid clearance from the eye surface. To address these problems, hydrogel-based materials were designed to detect biomarkers or act as drug delivery systems by taking advantage of their good biocompatibility, excellent physical and mechanical properties, and long-term implant stability. Biosensors prepared using biocompatible hydrogels can be sensitive in diagnosing DED, and the designed hydrogels can also improve the drug bioavailability and retention time for more effective and long-term treatment. This review summarizes recent advances in the use of hydrogels for diagnosing and treating dry eye, aiming to provide a novel reference for the eventual clinical translation of hydrogels in the context of dry eye disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.